ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 123 citations in OpenAlex.
- Association of regulatory B, T cells and cytokine production with disease stage in non-small cell lung cancer patients: prospective case control study.BMC cancer · 2026Article
- Radiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements.Molecular carcinogenesis · 2026Review
- Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment.Journal for immunotherapy of cancer · 2026Review
- Metformin-A Type 2 Diabetes Mellitus Drug-And Ovarian Cancer: Anticancer Mechanisms and Therapeutic Implications.Biomolecules · 2026Review
- Prognostic model based on stem cells and oxidative stress related genes for ovarian cancer.Medicine · 2026Article
- Regulatory B Cells in Tumor Microenvironment.Current issues in molecular biology · 2026Review
- Intraperitoneal immune microenvironment and efficacy of intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastasis.Scientific reports · 2025Article
- The CD40/CD40L Pathway Regulates the Aggressiveness of Ovarian Cancer Cells via the Activation of Regulatory B Cells.Biochemical genetics · 2025Article
- Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy.Cell death & disease · 2025Review
- Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics.Molecular cancer · 2025Review
- Review: radiotherapy-mediated B cells within the TLS influence the tumor microenvironment.Journal for immunotherapy of cancer · 2025Review
- Review
- Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments.Trends in immunology · 2025Review
- Advances in tumor-infiltrating B lymphocytes.Central-European journal of immunology · 2025Review
- A Comprehensive Methodology for Immortalizing Tumor-Infiltrating B Lymphocytes from Epithelial Cancers.Methods in molecular biology (Clifton, N.J.) · 2025Article
- B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications.Theranostics · 2025Review
- Review
- Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2024Review
- The diagnostic value of selected immune parameters in peripheral blood of dogs with malignant mammary tumours - a preliminary study.Journal of veterinary research · 2024Article
- TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple factors in the tumor microenvironment were found to inhibit antitumor adaptive immune responses, allowing tumor persistence and growth. In this study, ascites from ovarian cancer patients were collected. We observed that a population of interleukin-10(+) B (IL-10(+) B) cells was preferentially enriched in the ascites. This population was associated with naive B cell phenotype or IgM or class-switched memory B cell phenotypes. The frequencies of IL-10(+) B cells were negatively correlated with the frequencies of interferon gamma-producing (IFN-g(+)) CD8(+) T cells and were positively correlated with the frequencies of Foxp3(+) CD4(+) T cells. To examine whether increased IL-10(+) B cells in ascites could directly result in increased suppression of IFN-g production by CD8(+) T cells, we cocultured CD8(+) T cells with autologous blood B cells or ascitic B cells and found that CD8(+) T cells cocultured with ascitic B cells demonstrated significantly suppressed IFN-g production. This suppression was in part mediated by IL-10 as well as low CD80/CD86 expression, since depletion of IL-10 and stimulation of CD28 partially reverted IL-10(+) B cell-mediated suppression. Together, these data demonstrated an additional regulatory mechanism in the tumor microenvironment, which utilizes IL-10(+) B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.